Values as of: 2024-09-21
COMMON STOCK | Biotechnology |
Last Closing
USD 3.8Change
0.00 (0.00)%Market Cap
USD 0.29BVolume
400.00Analyst Target
N/AVerdict
Verdict
MeiraGTx Holdings plc, a clinical stage gene therapy company, focusing on developing treatments for patients with serious diseases. The company develops various therapies for ocular diseases, including inherited retinal diseases and large degenerative ocular diseases, neurodegenerative diseases, and xerostomia. Its programs in clinical development include Phase I/II clinical stage programs in achromatopsia, X-linked retinitis pigmentosa, and RPE65-deficiency; Phase I clinical trials for radiation-induced xerostomia; and Parkinson's program that has completed a Phase II trial. It has a research collaboration agreement with Janssen Pharmaceuticals, Inc. for the research, development, and commercialization of gene therapies for the treatment of inherited retinal disease. The company was incorporated in 2015 and is based in New York, New York.
Company Website : https://meiragtx.com
Currency: EUR
Country : Germany
| Symbol | Name | Price(Change) | Market Cap |
|---|---|---|---|
| NOVA:F | Novo Nordisk A/S |
N/A |
USD 547.87B |
| NOV:F | Novo Nordisk A/S |
N/A |
USD 547.87B |
| RGO:F | Regeneron Pharmaceuticals Inc |
N/A |
USD 114.77B |
| CSJ:F | CSL Limited |
N/A |
USD 87.33B |
| CSJA:F | CSL LTD SPON.ADR 2 |
N/A |
USD 86.75B |
| DUL:F | Alnylam Pharmaceuticals Inc |
N/A |
USD 31.54B |
| UNC0:F | UCB S.A. UNSP.ADR 1/2 |
N/A |
USD 30.36B |
| 1AEA:F | argenx SE |
N/A |
USD 28.96B |
| 1AE:F | Argen-X |
N/A |
USD 28.63B |
| 22UA:F | BioNTech SE |
N/A |
USD 26.15B |
| Market Performance vs. Industry/Classification (Biotechnology) | Market Performance vs. Exchange | ||||||
| Value | Sector Median | Percentile Rank | Grade | Market Median | Percentile Rank | Grade | |
| YTD | |||||||
| Capital Gain | -40.16% | 28% | F | 12% | F | ||
| Dividend Return | N/A | N/A | N/A | N/A | N/A | ||
| Total Return | -40.16% | 28% | F | 12% | F | ||
| Trailing 12 Months | |||||||
| Capital Gain | -20.50% | 49% | F | 28% | F | ||
| Dividend Return | N/A | N/A | N/A | N/A | N/A | ||
| Total Return | -20.50% | 48% | F | 25% | F | ||
| Trailing 5 Years | |||||||
| Capital Gain | N/A | N/A | N/A | N/A | N/A | ||
| Dividend Return | N/A | N/A | N/A | N/A | N/A | ||
| Total Return | N/A | N/A | N/A | N/A | N/A | ||
| Average Annual (5 Year Horizon) | |||||||
| Capital Gain | -7.34% | 48% | F | 27% | F | ||
| Dividend Return | -7.34% | 48% | F | 24% | F | ||
| Total Return | N/A | N/A | N/A | N/A | N/A | ||
| Risk Return Profile | |||||||
| Volatility (Standard Deviation) | 14.25% | 91% | A- | 78% | C+ | ||
| Risk Adjusted Return | -51.51% | 40% | F | 23% | F | ||
| Market Capitalization | 0.29B | 66% | D+ | 43% | F | ||
| Target Price Action | Rating Action | Analyst | Rating | Price | Date |
|---|
This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.
The stock’s annual returns have been stable and consistent compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile. Although stability is good, also keep in mind it can limit returns.
This company is delivering below median risk adjusted returns in its peers. Even if it is outperforming on returns , the returns are unpredictable. Proceed with caution.
The stock is trading high compared to its peers median on a price to book value basis.
The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.
The company had negative total free cash flow in the most recent four quarters.
